A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...

Biologics, including medications like mepolizumab and dupilumab, are widely prescribed for patients with severe asthma and ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

SAN FRANCISCO — Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation rates and fewer ED visits per exacerbation at 104 ...

Mepolizumab is the only approved biologic evaluated in patients with an eosinophilic phenotype characterized by a blood eosinophil count (BEC) threshold as low as ≥150 cells/µL. 1,2 BEC is ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Among those diagnosed with COPD for at least 9 years, mepolizumab reduced the annualized rate of moderate or severe exacerbations by 24% compared with placebo (95% CI, 0.60-0.97).

The researchers found that the annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than placebo (0.80 vs 1.01 events per year; rate ratio, 0.79).

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...

At 12 months, however, a statistically significantly higher complete response rate was reported in the benralizumab arm vs the mepolizumab arm (48.1% vs 32.4%, respectively; P =.005).